Latest news about Lasa Supergenerics
Lasa Supergenerics
4.91
-0.25(-4.84%)
Company Performance:
View Company Insights1D-4.84%
1M0.00%
6M-39.23%
1Y-51.34%
5Y0.00%
More news about Lasa Supergenerics
30May 26
Lasa Supergenerics narrows net loss to ₹416.44 lakh in Q4FY26
Lasa Supergenerics narrowed its net loss to ₹416.44 lakh for Q4FY26 from ₹1,429.11 lakh in Q4FY25, with revenue from operations falling to (₹13.15) lakh due to a production halt caused by a fire incident. The statutory auditor, Gupta Rustagi & Co., issued a qualified opinion due to insufficient evidence on the fire's financial impact and the lack of impairment assessment for intangible assets worth ₹1,667.05 lakh. For the full year FY26, the company reported a net loss of ₹3,409.03 lakh on a total income of ₹2,534.05 lakh, while facing operational challenges like labour unrest.
19May 26
Lasa Supergenerics Board Meeting Scheduled on May 29, 2026 to Approve Q4 FY26 Audited Financial Results
Lasa Supergenerics has intimated stock exchanges of a board meeting scheduled for May 29, 2026, pursuant to Regulation 29 of the SEBI (LODR) Regulations, 2015. The meeting will consider and approve the audited financial results for the quarter and year ended March 31, 2026. The company's trading window will remain closed until 48 hours after the declaration of results, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The intimation, dated May 19, 2026, was signed by Director Ganesh Potdar (DIN: 11455401).
16Apr 26
LASA Supergenerics Declares Non-Applicability of Large Entities Framework Under SEBI Guidelines
LASA Supergenerics Limited has declared to BSE and NSE that it does not fall under the Large Corporate category as per SEBI Circular dated November 26, 2018. The declaration, submitted on April 16, 2026, confirms the company's exemption from the Large Entities framework for debt securities issuance, ensuring compliance with regulatory transparency requirements.
14Feb 26
Lasa Supergenerics Board Approves Q3FY26 Results Showing Rs 255.47 Lakh Loss
Lasa Supergenerics Limited's Board approved Q3FY26 financial results showing continued losses due to operational suspension following a May 2025 fire incident. The company reported a net loss of Rs 255.47 lakh with dramatically reduced revenue, while exploring alternative manufacturing arrangements subject to regulatory approvals.
02Jan 26
LASA Supergenerics Appoints Ganesh Potdar as Additional Executive Director
LASA Supergenerics Limited appointed Mr. Ganesh Suresh Potdar as Additional Director in Executive capacity and Occupier of all units on January 02, 2026. The appointment, approved during a board meeting, is subject to member approval at the next General Meeting or Postal Ballot. Mr. Potdar brings expertise in business operations, banking processes, and financial coordination to strengthen the company's leadership team.
15Dec 25
Lasa Supergenerics Appoints Mrs. Mitti Jain as Company Secretary and Compliance Officer
Lasa Supergenerics Limited has appointed Mrs. Mitti Jain as the new Company Secretary and Compliance Officer, effective December 16, 2025. Mrs. Jain, an Associate Member of the Institute of Company Secretaries of India, brings 10 years of experience in corporate laws and allied matters. She holds B.Com and M.Com degrees from the University of Gujarat. The appointment complies with Section 203 of the Companies Act, 2013 and SEBI LODR Regulation 6(1).
11Dec 25
Lasa Supergenerics Whole-time Director Prathmesh Chalke Resigns Effective December 31, 2025
Lasa Supergenerics Limited announced the resignation of Whole-time Director Mr. Prathmesh Chalke (DIN: 11119348), effective December 31, 2025. The director confirmed no material reasons for resignation beyond those in his December 11, 2025 letter, expressing gratitude for his tenure and commitment to smooth transition. The company informed BSE and NSE in compliance with SEBI Regulation 30 requirements.
14Nov 25
Lasa Supergenerics Reports Rs 2,821.93 Crore Loss Following Devastating Factory Fire
Lasa Supergenerics Limited reported a net loss of Rs 2,821.93 crore for Q2 ending September 30, primarily due to a fire at its main manufacturing facility in May. The fire destroyed inventories and equipment worth Rs 1,973.62 crore, leading to a halt in all manufacturing operations. The company is exploring contract manufacturing and facility leasing options to resume business, subject to regulatory approvals. Auditors have highlighted the fire's impact as exceptional items in their review report.
22Sept 25
LASA Supergenerics' Company Secretary Resigns Citing Non-Operational Status
Mrs. Mitti Jain, Company Secretary and Compliance Officer of Lasa Supergenerics Limited, has resigned effective August 29. Her resignation letter, initially omitted but later included in a revised disclosure to stock exchanges, cites the company's non-operational status and absence of active business operations as reasons for stepping down. The resignation raises questions about Lasa Supergenerics' current operational state.
05Aug 25
LASA Supergenerics Bolsters Board with Four New Independent Directors
Lasa Supergenerics Limited has appointed four new Additional Directors as Non-Executive Independent Directors for a five-year term starting August 05, 2025. The new directors are Mr. Ketan Bhau Songal (Agro-Veterinary Sciences expert), Mr. Pravin Gadalya Lachake (Poultry operations specialist), Mr. Yogesh Hari Ughada (Animal care professional), and Mrs. Rekha Hemant Wakh (Animal Nutrition specialist). These appointments aim to enhance the company's leadership and bring diverse expertise in veterinary sciences, poultry operations, animal care, and nutrition to its governance structure. The appointments are subject to shareholder approval and comply with SEBI regulations.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Laurus Labs
Zydus Life Science
Cipla
Dr Reddys Laboratories
Aurobindo Pharma
Mankind Pharma
Lupin
1,743.00
(-0.90%)
9,087.00
(-0.63%)
4,558.70
(+0.00%)
2,069.00
(+0.43%)
1,113.90
(-0.81%)
1,324.10
(-0.08%)
1,242.50
(+0.77%)
1,621.40
(-2.73%)
2,253.20
(-0.98%)
1,939.20
(-1.14%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
